GlobeNewswire Inc | Apr 20, 2021 10:56AM EDT

April 20, 2021

PRINCETON, N.J., April 20, 2021 (GLOBE NEWSWIRE) -- In a release issued earlier today by Agile Therapeutics, Inc. (Nasdaq: AGRX), please note the headline should read "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021" instead of "Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2020". The corrected release follows:

Agile Therapeutics to Report First Quarter 2021 Financial Results and Provide Business Update on Tuesday, May 4, 2021

Live Conference Call and Webcast at 4:30 p.m. EDT

Agile Therapeutics, Inc.(Nasdaq: AGRX), a womens healthcare company, today announced it will report first quarter 2021 financial results after the market close onTuesday, May 4, 2021 as follows:

Date Tuesday, May 4, 2021Time 4:30 p.m. EDTWebcast (live and archived) Events & PresentationsDial-in numbers (866) 324-3683 (U.S. toll-free) or (509) 844-0959Conference ID 2334548

Investors interested in listening to the conference call may do so by dialing (866) 324-3683 for domestic callers or (509) 844-0959 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.

Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

AboutAgile Therapeutics, Inc.Agile Therapeuticsis a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of todays women.Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method.Our initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. For more information, please visit the company website atwww.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Companys website.

Contact:Matt RileyHead of Investor Relations & Corporate Communicationsmriley@agiletherapeutics.com